Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen EVasc Health Risk Manag 2007[]; 3 (4): 467-79Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high total-cholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDL-cholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan in a usual-care setting. The most common side-effect of Niaspan is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1-2 years of treatment with Niaspan plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.|Atorvastatin[MESH]|Azetidines/therapeutic use[MESH]|Cholesterol, HDL/drug effects[MESH]|Delayed-Action Preparations[MESH]|Drug Therapy, Combination[MESH]|Dyslipidemias/*drug therapy[MESH]|Ezetimibe[MESH]|Fluorobenzenes/therapeutic use[MESH]|Heptanoic Acids/therapeutic use[MESH]|Humans[MESH]|Hypolipidemic Agents/*therapeutic use[MESH]|Niacin/*therapeutic use[MESH]|Pyrimidines/therapeutic use[MESH]|Pyrroles/therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH]|Rosuvastatin Calcium[MESH]|Simvastatin/therapeutic use[MESH]|Sulfonamides/therapeutic use[MESH] |